Jung Im Seok, Dong Kuck Lee, Chang Hyeong Lee, Min Su Park, Sun Young Kim, Hyang‐Sook Kim, Hee‐Young Jo, Chang Hun Lee, Dae‐Seong Kim – 28 May 2009 – Clevudine (Revovir), a pyrimidine nucleoside analogue, is a recently introduced antiviral drug. Clinical trials have demonstrated potent, sustained antiviral activity against hepatitis B virus without specific adverse events. The lack of cytotoxicity and absence of an effect on mitochondrial function have been considered the reasons for the fewer adverse events.

Patrizia Burra, Massimiliano Loreno, Francesco Paolo Russo, Giacomo Germani, Alessandra Galligioni, Marco Senzolo, Umberto Cillo, Giacomo Zanus, Stefano Fagiuoli, Massimo Rugge – 28 May 2009 – Whether donor graft steatosis affects liver function and influences survival after liver transplantation is still open to debate. The aim of this study was to assess the impact of donor graft steatosis on long‐term liver histology after liver transplantation.

Sandy Feng – 28 May 2009

Akihito Inatsu, Manabu Kinoshita, Hiroyuki Nakashima, Jun Shimizu, Daizoh Saitoh, Seiichi Tamai, Shuhji Seki – 28 May 2009 – Although C‐reactive protein (CRP) is a representative acute‐phase protein produced by hepatocytes, the role of CRP in liver innate immunity remains unclear.

Kerry‐Lee Milner, David van der Poorten, Aimin Xu, Elisabetta Bugianesi, James G. Kench, Karen S. L. Lam, Donald J. Chisholm, Jacob George – 28 May 2009 – Several circulating cytokines are increased with obesity and may combine with the influence of visceral fat to generate insulin resistance, inflammation, and fibrosis in nonalcoholic fatty liver disease (NAFLD).

Anthony W. Castleberry, David A. Geller, Allan Tsung – 28 May 2009

Yasuji Arase – 28 May 2009

Anand N. Bhatt, David H. Adams – 28 May 2009

Ester Vanni, Elisabetta Bugianesi – 28 May 2009

Daniel G. Maluf, Erick B. Edwards, R. Todd Stravitz, H. Myron Kauffman – 28 May 2009 – We have investigated the impact of the donor risk index (DRI) on the outcome of hepatitis C virus (HCV)–infected patients undergoing liver transplantation (LTx). Retrospective analysis was performed from the Organ Procurement and Transplantation Network database (January 1, 2000 to June, 2006). The DRI was calculated as described by Feng et al. (Am J Transplant 2006;6:783–790). Model for End‐Stage Liver Disease (MELD) exceptions were excluded from the analysis.